✦ LIBER ✦

W1092 Maintenance of Long-Term Remission in Patients with Moderately to Severely Active Crohn's Disease Treated for 3 Years with Adalimumab: Results from the Open-Label ADHERE Study

✍ Scribed by Rutgeerts, Paul; Colombel, Jean-Frederic; Sandborn, William J.; Rutgeerts, Paul J.; D'Haens, Geert R.; Lomax, Kathleen G.; Li, Ju; Pollack, Paul F.

Book ID: 122013473
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 99 KB
Volume: 136
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(09)63006-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P148 - Adalimumab maintains long-term re

P148 - Adalimumab maintains long-term remission in patients with moderately to severely active Crohn's disease through 3 years of therapy

✍ R. Panaccione; J.F. Colombel; W.J. Sandborn; P. Rutgeerts; G. D'Haens; K.G. Loma 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 61 KB

P068 NATALIZUMAB MAINTAINS REMISSION FOR

P068 NATALIZUMAB MAINTAINS REMISSION FOR 2 YEARS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE AND IN THOSE WITH PRIOR INFLIXIMAB EXPOSURE: RESULTS FROM AN OPEN-LABEL EXTENSION STUDY

✍ G. D'Haens; F. Baert; P. Rutgeerts; R. Panaccione 📂 Article 📅 2007 🏛 Oxford University Press ⚖ 58 KB

Long-term efficacy and safety of adalimu

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL

✍ Kenneth Gordon; Kim Papp; Yves Poulin; Yihua Gu; Stephen Rozzo; Eric H. Sasso 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 347 KB

W1096 Results from An Open-Label Extensi

W1096 Results from An Open-Label Extension of CHARM: Steroid-Free Remission in Patients with Crohn's Disease Who Received Adalimumab Therapy for At Least 3 Years

✍ Kamm, Michael A.; Hanauer, Stephen B.; Rutgeerts, Paul; Colombel, Jean-Frederic; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 117 KB

OP009 Long-term safety and efficacy of g

OP009 Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extension

✍ Reinisch, W.; Gibson, P.; Sandborn, W.J.; Feagan, B.G.; Marano, C.; Strauss, R.; 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 65 KB

Mo1214 Long-Term Safety and Efficacy of

Mo1214 Long-Term Safety and Efficacy of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the PURSUIT-SC Maintenance Study Extension

✍ Gibson, Peter R.; Reinisch, Walter; Sandborn, William; Feagan, Brian G.; Marano, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 190 KB